Intercept Pharmaceuticals Management

Management Kriterienprüfungen 3/4

Intercept Pharmaceuticals CEO ist Jerry Durso , ernannt in Jan 2021, hat eine Amtszeit von 2.42 Jahren. Die jährliche Gesamtvergütung beträgt $4.46M , bestehend aus 16% Gehalt und 84% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.12% der Aktien des Unternehmens, im Wert von MX$10.62M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.3 Jahre bzw. 9.1 Jahre.

Wichtige Informationen

Jerry Durso

Geschäftsführender

US$4.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	16.0%
Amtszeit als Geschäftsführer	2.4yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	2.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	9.1yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Jerry Durso im Vergleich zu den Einnahmen von Intercept Pharmaceuticals verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2023	n/a	n/a	-US$173m
Dec 31 2022	US$4m	US$715k	-US$175m
Sep 30 2022	n/a	n/a	-US$202m
Jun 30 2022	n/a	n/a	-US$115m
Mar 31 2022	n/a	n/a	-US$120m
Dec 31 2021	US$8m	US$691k	-US$136m
Sep 30 2021	n/a	n/a	-US$144m
Jun 30 2021	n/a	n/a	-US$193m
Mar 31 2021	n/a	n/a	-US$231m
Dec 31 2020	US$4m	US$600k	-US$273m
Sep 30 2020	n/a	n/a	-US$321m
Jun 30 2020	n/a	n/a	-US$339m
Mar 31 2020	n/a	n/a	-US$347m
Dec 31 2019	US$4m	US$573k	-US$345m
Sep 30 2019	n/a	n/a	-US$335m
Jun 30 2019	n/a	n/a	-US$314m
Mar 31 2019	n/a	n/a	-US$318m
Dec 31 2018	US$3m	US$541k	-US$309m
Sep 30 2018	n/a	n/a	-US$333m
Jun 30 2018	n/a	n/a	-US$341m
Mar 31 2018	n/a	n/a	-US$352m
Dec 31 2017	US$4m	US$441k	-US$360m

Vergütung im Vergleich zum Markt: JerryDie Gesamtvergütung ($USD4.46M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt MX ($USD242.67K).

Entschädigung vs. Einkommen: JerryDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Jerry Durso (55 yo)

2.4yrs

Amtszeit

US$4,455,463

Vergütung

Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jerome Durso	President	2.4yrs	US$4.46m	0.12% MX$ 10.6m
Andrew Saik	Chief Financial Officer	2yrs	US$1.39m	0.036% MX$ 3.1m
Jared Freedberg	General Counsel	2.3yrs	US$1.31m	0.14% MX$ 11.9m
Linda Richardson	Executive VP & Chief Commercial Officer	2.3yrs	US$1.34m	0.040% MX$ 3.4m
M. Berrey	President of Research & Development and Chief Medical Officer	2yrs	US$1.61m	0.054% MX$ 4.6m
Rocco Venezia	Chief Accounting Officer & Treasurer	2.3yrs	US$856.23k	0.061% MX$ 5.2m
Nareg Sagherian	Executive Director of Global Investor Relations	1.5yrs	keine Daten	keine Daten
David Ford	Chief Human Resources Officer	6.1yrs	US$1.91m	0.060% MX$ 5.1m
Mark Pruzanski	Founder	2.4yrs	US$6.43m	1.48% MX$ 126.8m
Paul Nitschmann	Senior Vice President of Regulatory Affairs	no data	keine Daten	keine Daten
Kathleen Munster	Chief Quality Officer & SVP of Technical Operations	less than a year	keine Daten	keine Daten
Michael Blash	Senior Vice President of Corporate Affairs	less than a year	keine Daten	keine Daten

2.3yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: ICPT *Das Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jerome Durso	President	2.1yrs	US$4.46m	0.12% MX$ 10.6m
Mark Pruzanski	Founder	21.4yrs	US$6.43m	1.48% MX$ 126.8m
Daniel Bradbury	Independent Director	6.9yrs	US$327.39k	0.056% MX$ 4.8m
Glenn Sblendorio	Independent Director	9.3yrs	US$332.39k	0.056% MX$ 4.8m
Luca Benatti	Independent Director	8.9yrs	US$327.39k	0.061% MX$ 5.2m
Srinivas Akkaraju	Independent Director	10.7yrs	US$317.39k	0.091% MX$ 7.8m
Gino Santini	Lead Independent Director	7.6yrs	US$337.39k	0.057% MX$ 4.8m
Paolo Fundaro	Independent Chairman of the Board	17.1yrs	US$342.39k	0.086% MX$ 7.3m
Alan Hofmann	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
Scott Friedman	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
Massimo Pinzani	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
Aldo Roda	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten

9.1yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrener Vorstand: ICPT *Die Vorstandsmitglieder gelten als erfahren (9.1 Jahre durchschnittliche Amtszeit).

Intercept Pharmaceuticals Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Recent updates

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast breakeven date moved forward to 2022

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter